14-day Premium Trial Subscription Sign Up For FreeGet Free

Cardiovascular Systems Stock News NASDAQ:CSII

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). The first patients in Canada were treated by Sanjog Kalra, MD, Interventional Cardiologist and Cardiac Critical Care P Read more
New York, United States: The industry analysis Atherectomy Devices Market report by Decisive Markets Insights includes the market''s key elements like revenue growth, market prognosis (2021-2027), customer preferences, company strategies, performance metrics, COVID-19''s impact on the global market, value chain Read more

Cardiovascular Systems EPS misses by $13.83, beats on revenue

08:21pm, Wednesday, 04'th Aug 2021 Seeking Alpha
Read more
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial Results Read more
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to attend three investor conferences in August. Guggenheim MedTech Disruptors Summit Tuesday, August 10, 2021 Canaccord Genuity 41st Annual Growth Conference Wednesday, August 11, 2021 12:30 p.m. ET Webcast of present Read more
Shares of Cardiovascular Systems Inc. , a medical device company focused on treatments for vascular and coronary disease, tumbled 10.2% in afternoon trading, and has dropped 18.1% amid a four-day losing streak. Needham analyst Mike Matson noted that the Centers for Medicare & Medicaid Services'' (CMS) proposed physician fee schedule for 2022 includes cuts of about 22% to office-based lab (OBL) payments for peripheral atherectomy. He expects medical societies to oppose to the fee schedule changes. "We do not expect this to have much, if any, impact on [Cardiovascular Systems] even if the cuts happen," Matson said, because he believes the proposed codes leave plenty of profit for the OBL, OBLs account for only about one-fifth of the company''s overall sales and the company continued to see strong growth in its OBL business last year even though there were high single-digit cuts to OBL payments. "We are buyers on weakness," Matson said, as he reiterated his buy rating and $50 stock price target. Read more
Northland Securities Stick to Their Buy Rating for Cardiovascular Systems Read more
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that management plans to present and host investor meetings at the Raymond James Human Health Innovations Conference on June 23rd. Read more
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that the full line of OrbusNeich® JADE® percutaneous transluminal angioplasty over-the-wire balloon catheters is now available in the U.S. Read more
Cardiovascular Systems (CSII) received a Buy rating and a $50.00 price target from Leerink Partners analyst Danielle Antalffy on May 28. The post Cardiovascular Systems (CSII) Initiated with a Buy at Leerink Partners appeared first on Smarter Analyst . Read more
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-world optical coherence tomography (OCT) imaging study of coronary OAS patients were released at EuroPCR 2021. The study conducted by Surendra Avula, MD, et The post New Study Demonstrates Exceptional Performance With Cardiovascular Systems Diamondback 360 Coronary Orbital Atherectomy System (OAS) Dual Mode of Action first appeared on Financial Buzz . Read more
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that results from a real-world optical coherence tomography imaging study of coronary OAS patients were released at EuroPCR 2021. Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE